Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by boazklinghornon Sep 22, 2023 3:19pm
68 Views
Post# 35649896

RE:RE:RE:RE:RE:RE:re: ' Thank me later' ?.......I HAVE BEEN F***** SCREAMING

RE:RE:RE:RE:RE:RE:re: ' Thank me later' ?.......I HAVE BEEN F***** SCREAMINGRight so once again you make my point, what you offered as guidance is not guidance. 
Gilles may have said that a complete collapse of revenue in H1 was "a glitch". I believe he  also characterized the failure of a potentially transformative 2 year clinical trial as "A bump in the road"
He can never be trusted to tell shareholders the truth and we just have to wait for Q3 to see how bad it is. 
<< Previous
Bullboard Posts
Next >>